SV2003001495A - OXO-AZABICICLIC COMPOUNDS - Google Patents

OXO-AZABICICLIC COMPOUNDS

Info

Publication number
SV2003001495A
SV2003001495A SV2003001495A SV2003001495A SV2003001495A SV 2003001495 A SV2003001495 A SV 2003001495A SV 2003001495 A SV2003001495 A SV 2003001495A SV 2003001495 A SV2003001495 A SV 2003001495A SV 2003001495 A SV2003001495 A SV 2003001495A
Authority
SV
El Salvador
Prior art keywords
group
rent
inclusive
formula
whole number
Prior art date
Application number
SV2003001495A
Other languages
Spanish (es)
Inventor
Henry Jacobelli
Catherine Kostlan
Jack Jie Li
Wen-Song Yue
Bernard Gaudilliere
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2003001495A publication Critical patent/SV2003001495A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO SELECCIONADO DE AQUELLOS DE LA FORMULA (I) EN DONDE X1, X2, Y X3 REPRESENTAN N O -CR3 EN DONDE R3 ES LO DESCRIPTO EN LA MEMORIA DESCRIPTIVA,G1 REPRESENTA UN GRUPO SELECCIONADO DE AQUELLOS DE LAS FORMULAS )I/A) E (I/B): EN DONDE R4, R5 Y R6 SON LO DEFINIDO ANTERIORMENTE,G2 REPRESENTA UN GRUPO SELECCIONADO DE ENLACE TRIPLE DE CARBONO-CARBONO.-CH=C=CH -, C=0, C=S,S(0) NL EN DONDE NI REPRESENTA UN NUMERO ENTERO DE 0 A 2 INCLUSIVE, Y UN GRUPO DE LA FORMULA (I/C)EN DONDE Y1 REPRESENTA 0,S, -NH O N ALQUILO,N ES UN NUMERO ENTERO DE 0 A 6 INCLUSIVE, Y M ES UN NUMERO ENTERO DE 0 A 7 INCLUSIVE,Z1 REPRESENTA -CR9R10, EN DONDE R9 Y R10 SON LO DEFINIDO EN LA MEMORIA DESCRIPTIVA,A REPRESENTA UN SISTEMA DE ANILLO,R1 REPRESENTA UN GRUPO SELECCIONADO DE H, ALQUILO, ALQUENILO, ALQUINILO, OPTATIVAMENTE SUSTITUIDO Y EL GRUPO DE LA FORMULA (I/D) EN DONDE P, Z2, B Q Y G2 SON LO DEFINIDO EN LA MEMORIA DESCRIPTIVA Y OPTATIVAMENTE , SUS ISOMEROS OPTICOS, N-OXIDOS Y SALES DE ELLOS CON EL ACIDO O BASE FARMACEUTICAMENTEACEPTABLE, Y PRODUCTOS MEDICINALES QUE CONTIENEN LOS MISMOS SON UTILES COMO INHIBIDORES ESPECIFICOS DE LA METALOPROTEASA DE LA MATRIZ DE TIPO 13.A SELECTED COMPOSITE OF THOSE OF THE FORMULA (I) WHERE X1, X2, AND X3 REPRESENT NO -CR3 WHERE R3 IS WHAT IS DESCRIBED IN THE DESCRIPTIVE MEMORY, G1 REPRESENTS A SELECTED GROUP OF THOSE OF THE FORMULAS) I / A) E (I / B): WHERE R4, R5 AND R6 ARE THE DEFINED ABOVE, G2 REPRESENTS A SELECTED GROUP OF CARBON-CARBON TRIPLE LINK.-CH = C = CH -, C = 0, C = S, S (0 ) NL WHERE OR REPRESENTS A WHOLE NUMBER OF 0 TO 2 INCLUSIVE, AND A FORMULA GROUP (I / C) WHERE Y1 REPRESENTS 0, S, -NH ON RENT, N IS A WHOLE NUMBER OF 0 TO 6 INCLUSIVE, YM IS A WHOLE NUMBER OF 0 TO 7 INCLUSIVE, Z1 REPRESENTS -CR9R10, WHERE R9 AND R10 ARE THE DEFINED IN THE DESCRIPTIVE MEMORY, A REPRESENTS A RING SYSTEM, R1 REPRESENTS A SELECTED GROUP OF H, RENT, RENT, ALQUINYL, OPTIONALLY REPLACED AND THE FORMULA (I / D) GROUP WHERE P, Z2, BQY G2 ARE THE DEFINED IN THE DESCRIPTIVE AND OPTIONALLY MEMORY, ITS OPTICAL, N-OXID AND SALAD ISOMERS OF THEM WITH THE ACID OR BAS E PHARMACEUTICALLY ACCEPTABLE, AND MEDICINAL PRODUCTS CONTAINING THE SAME ARE USEFUL AS SPECIFIC INHIBITORS OF THE METALOPROTEASE OF THE TYPE MATRIX 13.

SV2003001495A 2002-03-08 2003-03-04 OXO-AZABICICLIC COMPOUNDS SV2003001495A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds

Publications (1)

Publication Number Publication Date
SV2003001495A true SV2003001495A (en) 2003-11-04

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001495A SV2003001495A (en) 2002-03-08 2003-03-04 OXO-AZABICICLIC COMPOUNDS

Country Status (25)

Country Link
EP (1) EP1492775A2 (en)
JP (1) JP2005526070A (en)
KR (1) KR20040095270A (en)
CN (1) CN1738806A (en)
AP (1) AP2004003125A0 (en)
AR (1) AR039562A1 (en)
AU (2) AU2002249275A1 (en)
BR (1) BR0308280A (en)
CA (1) CA2478706A1 (en)
CO (1) CO5601020A2 (en)
EA (1) EA200401053A1 (en)
EC (1) ECSP045278A (en)
IL (1) IL163818A0 (en)
IS (1) IS7414A (en)
MA (1) MA27183A1 (en)
MX (1) MXPA04008681A (en)
NO (1) NO20044041L (en)
OA (1) OA12782A (en)
PA (1) PA8568501A1 (en)
PE (1) PE20031018A1 (en)
PL (1) PL372622A1 (en)
SV (1) SV2003001495A (en)
TN (1) TNSN04169A1 (en)
UY (1) UY27700A1 (en)
WO (2) WO2003076416A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co TRIAZOLO COMPOUNDS AS MMP INHIBITORS
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
EP1537090A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1553949B1 (en) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (en) 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001786A (en) 2002-08-13 2005-04-25 Warner Lambert Co Azaisoquinoline derivatives as matrix metalloproteinase inhibitors.
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003253176A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (en) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
MXPA06012333A (en) * 2004-04-30 2007-01-17 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor.
WO2005123696A1 (en) * 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
CN101522676A (en) 2006-10-05 2009-09-02 Cv医药有限公司 Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl CoA desaturase inhibitors
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (en) * 2013-09-24 2016-01-13 西安交通大学 3-benzyl-4-quianzolinones and synthetic method thereof and application
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
JP6898919B2 (en) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． New compound
MX2018003564A (en) 2015-09-23 2018-06-18 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer.
FR3046793B1 (en) * 2016-01-14 2018-01-05 Les Laboratoires Servier NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946095A1 (en) * 1996-12-17 1999-10-06 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
PA8539401A1 (en) * 2001-02-14 2002-10-28 Warner Lambert Co QUINAZOLINAS AS INHIBITORS OF MMP-13
PA8539301A1 (en) * 2001-02-14 2002-09-30 Warner Lambert Co INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX

Also Published As

Publication number Publication date
WO2003076417A2 (en) 2003-09-18
PE20031018A1 (en) 2004-01-09
ECSP045278A (en) 2004-10-26
IL163818A0 (en) 2005-12-18
MA27183A1 (en) 2005-01-03
KR20040095270A (en) 2004-11-12
AU2002249275A1 (en) 2003-09-22
UY27700A1 (en) 2003-10-31
CN1738806A (en) 2006-02-22
JP2005526070A (en) 2005-09-02
EA200401053A1 (en) 2005-04-28
AP2004003125A0 (en) 2004-09-30
TNSN04169A1 (en) 2007-03-12
CO5601020A2 (en) 2006-01-31
BR0308280A (en) 2004-12-28
AU2003212307A1 (en) 2003-09-22
PA8568501A1 (en) 2003-12-19
AR039562A1 (en) 2005-02-23
IS7414A (en) 2004-08-19
OA12782A (en) 2006-07-10
EP1492775A2 (en) 2005-01-05
NO20044041L (en) 2004-10-07
WO2003076416A1 (en) 2003-09-18
MXPA04008681A (en) 2004-12-06
PL372622A1 (en) 2005-07-25
WO2003076417A3 (en) 2003-11-13
CA2478706A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
SV2003001495A (en) OXO-AZABICICLIC COMPOUNDS
SV2003000876A (en) QUINAZOLINAS AS INHIBITORS OF MMP-13
AR008377A1 (en) A COMPOUND DERIVED FROM 3-AROYLBENCIL-PIRIDAZINONE, A PARTICULAR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES CONTAINING SUCH A COMPOUND
UY26505A1 (en) SUBSTITUTED PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES
ECSP045003A (en) New dihydro-pteridinones, procedures for their preparation and their use as medicines.
ES2128277T3 (en) NEW DERIVATIVES OF PEPTIDES.
PA8491001A1 (en) MONOAMINE RECOVERY INHIBITORS FOR THE TREATMENT OF CNS DISORDERS.
PA8582801A1 (en) NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE
ES2169248T3 (en) AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR009938A1 (en) NEW ARILGLYCINAMIDE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
ES2178055T3 (en) SUBSTITUTED AMINIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2159922T3 (en) NEW DERIVATIVES OF BENCIMIDAZOL, BENZOXAZOL AND BENZOTIAZOL, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2183492T3 (en) NEW NITRON DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2167021T3 (en) ACID DERIVATIVES 4-BIFENIL-4-HYDROXIBUTIRIC SUBSTITUTED AS METALOPROTEASE MATRIX INHIBITORS.
ES2032752T3 (en) PREPARATION PROCEDURE FOR 1-BENZENOSULFONYL-2-OXO-5-ALCOXY-PIRROLIDINE DERIVATIVES.
UY26501A1 (en) SUBSTITUTED PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES
AR001769A1 (en) Benzamide enterokinetics pharmaceutical compositions containing them, a process for the preparation of said pharmaceutical compositions, the use of said compounds for the manufacture of medicines and a process for their preparation.
ES2037709T3 (en) HETERO-CYCLE DERIVATIVES OF SIX MEMBERS OF N, N'-DIACILHIDRAZINAS N'-SUBSTITUTED.
ES2029879T3 (en) PROCEDURE FOR PRODUCING SUBSTITUTED AMINE DERIVATIVES.
ES2172023T3 (en) NEW SUBSTITUTED TETRAHYDRA-PYRIDINIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2053455T3 (en) BASICALLY SUBSTITUTED PHENYLACETONITRILS, THEIR OBTAINING AND THE MEDICINES CONTAINING THEM.
AR004484A1 (en) NEW 1,2,3,4-TETRAHIDRO-2-NAFTALENAMINAS FENILO-SUBSTITUTED IN THE AROMATIC RING, ITS PREPARATION, ITS THERAPEUTIC APPLICATIONS AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2157539T3 (en) DERIVATIVES OF BENZOPIRANE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR035601A1 (en) PROCESSES OF PREPARATION OF INHIBITORS OF THE SODIUM-HYDROGEN EXCHANGER OF TYPE 1, INHIBITORS, SALES OF SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME IN THE PREPARATION OF MEDICINES
ES2062997T3 (en) SUBSTITUTED VINYLCEPHALOSPORINS, PROCEDURE FOR THEIR MANUFACTURE AND USE AS A MEDICINAL PRODUCT.

Legal Events

Date Code Title Description
FD Lapse